ONA, OTCQBNANF) chief medical officer Dr Carman Giacomantonio joined Proactive to discuss a critical development in the company's gold nanorod cancer therapy. Dr Giacomantonio talked about the company's progress as it moves toward its first-in-human clinical trial for patients with melanoma that has not responded to standard immunotherapy. 